Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Adam Elsesser, CEO and director of Penumbra, Inc. (PEN), reported transactions dated 09/03/2025 under a Rule 10b5-1 plan. He exercised 27,980 stock options with a $30 exercise price, resulting in acquisition of 27,980 shares. Following the exercise and planned sales to satisfy exercise price and tax withholding, he sold a total of 15,800 shares in multiple trades at weighted average prices of $268.41, $269.26, $270.09, and $270.81 (execution ranges disclosed). After these transactions he directly beneficially owns 182,460 shares; an additional 577,582 shares are held indirectly by the Siegel/Elsesser Revocable Trust. All exercised shares were vested and exercisable.
Penumbra Inc executive Johanna Roberts, EVP, General Counsel & Secretary, reported selling 600 shares of common stock on September 2, 2025 in five open-market or private transactions, with reported prices reflecting weighted-average sale prices pursuant to a Rule 10b5-1 trading plan. Following these sales, she directly holds 64,857 shares, a portion of which is subject to vesting.
Penumbra, Inc. (PEN) Form 144 notice: An affiliated person proposes to sell 15,800 shares of common stock through Morgan Stanley Smith Barney on 09/03/2025. The shares were acquired the same day by stock option exercise and paid in cash. The filing reports an aggregate market value of $4,260,403.64 for the proposed sale and lists 38,999,129 shares outstanding for the issuer. The notice also discloses six prior open-market sales by the same person between 06/11/2025 and 08/20/2025, totaling 95,865 shares sold in the past three months, with separate gross proceeds reported for each trade. The filer attests there is no undisclosed material adverse information.
Penumbra, Inc. notice reports a proposed sale of 186 shares of common stock through Fidelity Brokerage Services with an aggregate market value of $50,627.34. The shares represent stock awards acquired from Penumbra, Inc. on 03/31/2025. The filing states the approximate date of sale as 09/02/2025 and identifies the NYSE as the exchange. The filer reports 38,999,129 shares outstanding for the class, and indicates no other sales by the person in the past three months.
Penumbra, Inc. appointed Ms. Narayan as President and approved related compensation and disclosure. The company disclosed that Ms. Narayan’s spouse is Founder and CEO of N28 Technologies, an IT service provider that has provided services to Penumbra under commercial agreements totaling approximately $2 million since January 1, 2024. Those transactions were reviewed and approved by the Nominating and Corporate Governance Committee under the company’s Related Person Transaction Policy. In connection with her appointment, the Compensation Committee approved a grant of restricted stock units valued at approximately $2.5 million, effective September 15, 2025, vesting in equal annual installments over four years subject to continued service. Adam Elsesser will remain Chairman and Chief Executive Officer.
Adam Elsesser, CEO and President of Penumbra, Inc. (PEN), exercised stock options and sold a portion of shares on 08/20/2025 under a Rule 10b5-1 plan. He exercised a stock option with a $30 exercise price to acquire 27,976 shares. On the same date he sold multiple blocks of common stock executed under his 10b5-1 trading plan: 459 shares at a weighted average price of $252.86, 9,114 shares at a weighted average price of $254.27, 6,227 shares at a weighted average price of $254.99, and 100 shares at $256.50. Following these transactions his direct beneficial ownership is reported as 170,280 shares. He also holds 577,582 shares indirectly through the Siegel/Elsesser Revocable Trust, all as reported on the Form 4.
Penumbra, Inc. (PEN) Form 144 notice: An insider intends to sell 15,900 shares of Penumbra common stock through Morgan Stanley Smith Barney on 08/20/2025, with an aggregate market value of $4,046,988.84. The shares were acquired the same day via a stock option exercise and paid in cash. The filing lists prior insider sales by the same person, ADAM ELSESSER, totaling six transactions from 05/28/2025 to 08/06/2025, selling between 15,885 and 16,300 shares per trade and generating gross proceeds ranging from $3.77M to $4.37M.
The filer certifies no undisclosed material adverse information. The document is a routine Rule 144 notice describing proposed sale details, acquisition method, broker, and recent insider sales; it does not include company financial results or commentary.
Maggie Yuen, Chief Financial Officer of Penumbra Inc. (PEN), reported insider transactions on Form 4 covering trades dated August 13 and August 15, 2025. On August 13 she disposed of 2,000 shares at $250 per share pursuant to a Rule 10b5-1 trading plan. On August 15 she acquired 724 shares at $158.30 and executed a stock option for 724 shares with a $158.30 exercise price that vests and is exercisable through December 15, 2029. Following these transactions she beneficially owns 13,667 shares in total, of which some shares are subject to vesting and 86 were purchased under the company ESPP on May 19, 2025.
The filing is signed by an attorney-in-fact and explicitly states the August 13 sale was made under a 10b5-1 plan; it also notes all option shares reported are vested and exercisable. No additional financial results or company guidance are included.
Penumbra Inc director Arani Bose reported open-market sales of 12,000 shares of common stock on August 13, 2025. The trades comprised 9,103 shares at $250.45 per share and 2,897 shares at $251.27 per share, executed under a Rule 10b5-1 trading plan.
The reported prices are weighted-average figures from multiple trades within price ranges of $250.00–$250.95 and $251.00–$251.79. After these transactions, Bose holds 558 shares directly and 290,261 shares indirectly through Bose Family Holdings II, LLC, with a portion of the holdings subject to vesting and certain direct/indirect transfers treated as mere changes in form of beneficial ownership under Section 16.
Penumbra director Thomas Wilder sold 372 shares of Penumbra common stock on 08/12/2025 at $240.16 per share under a Rule 10b5-1 trading plan. After the reported sale, the filing shows the reporting person beneficially owns 372 shares directly and 4,506 shares indirectly through the Thomas and Catharine Wilder Family Trust dated March 31, 2006. The Form 4 notes a portion of the directly held shares are subject to vesting.
The filing states transfers between direct and indirect holdings through the family trust are treated as changes in form of ownership exempt under Rule 16a-13.